Table: Eisai -2025/26 parent results
May 15 (Reuters)-
Eisai Co Ltd
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2026 Mar 31, 2025 Mar 31, 2027 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 386.26 376.40
(+2.6 pct) (+2.4 pct)
Operating 9.73 34.61
(-71.9 pct) (+50.2 pct)
Recurring 12.94 35.04
(-63.1 pct) (+43.1 pct)
Net 20.84 41.60
(-49.9 pct) (+104.8 pct)
EPS 73.94 yen 146.72 yen
Ann Div 160.00 yen 160.00 yen 160.00 yen
-Q2 Div 80.00 yen 80.00 yen 80.00 yen
-Q4 Div 80.00 yen 80.00 yen 80.00 yen
NOTE - Eisai Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4523.T
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China